Seres Therapeutics (MCRB) Projected to Post Earnings on Wednesday

Key Points

• Seres Therapeutics is set to announce its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($2.72) per share.
• The company's stock has increased by 4.4% recently, trading at $12.68, with a significant market capitalization of $110.70 million.
• Goldman Sachs raised its stake in Seres Therapeutics by 40.9%, reflecting increased institutional interest as 59.34% of the company's stock is currently owned by institutional investors.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Seres Therapeutics to post earnings of ($2.72) per share for the quarter.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). On average, analysts expect Seres Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seres Therapeutics Price Performance

Seres Therapeutics stock opened at $13.99 on Monday. The stock has a market capitalization of $122.13 million, a price-to-earnings ratio of -3.04 and a beta of 2.90. Seres Therapeutics has a 1-year low of $6.53 and a 1-year high of $26.40. The business has a fifty day moving average price of $10.33 and a 200-day moving average price of $11.93.

Institutional Trading of Seres Therapeutics

A hedge fund recently raised its stake in Seres Therapeutics stock. Invesco Ltd. increased its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 193.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 136,572 shares of the biotechnology company's stock after buying an additional 89,995 shares during the quarter. Invesco Ltd. owned about 1.56% of Seres Therapeutics worth $96,000 at the end of the most recent quarter. 59.34% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Chardan Capital reiterated a "neutral" rating and issued a $6.00 price objective (up from $1.25) on shares of Seres Therapeutics in a research note on Thursday, May 8th. Wall Street Zen upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Seres Therapeutics currently has an average rating of "Hold" and an average target price of $73.67.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.